Get the Stockscreener App
0.6203
2.71%
-0.0173
After Hours:
.62
-0.0003
-0.05%
Lexaria Bioscience Corp stock is traded at $0.6203, with a volume of 104.01K.
It is down -2.71% in the last 24 hours and down -19.43% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.6376
Open:
$0.68
24h Volume:
104.01K
Relative Volume:
0.18
Market Cap:
$15.44M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.4098
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
-6.30%
1M Performance:
-19.43%
6M Performance:
-25.58%
1Y Performance:
-59.19%
1-Day Range:
$0.6131
$0.68
1-Week Range:
$0.6131
$0.7949
52-Week Range:
$0.46
$1.8955
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.6203 | 15.87M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Analysts Set Expectations for LEXX FY2028 Earnings - Defense World
Quarterly Earnings: Is Lexaria Bioscience Corp a strong candidate for buy and holdMarket Growth Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Lexaria Bioscience Stock Price, News, Quote & History - Investing News Network
Bear Alert: Can Lexaria Bioscience Corp expand into new markets2025 Market WrapUp & Weekly Top Gainers Trade List - baoquankhu1.vn
Aug Swings: What is Lexaria Bioscience Corp Equity Warrants revenue forecastJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hedge Fund Moves: Does Lexaria Bioscience Corp have declining or rising EPSWeekly Stock Recap & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Lexaria Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lexaria’s Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study - TipRanks
Lexaria Bioscience (LEXX) Demonstrates Promising Results in Late - GuruFocus
Lexaria Announces Positive Final Results from Human Pilot Study #5 - Investing News Network
Lexaria Announces Positive Final Results From Human Pilot Study #5 - Corsicana Daily Sun
Experimental liraglutide pill shows similar results, 67% less nausea - Stock Titan
Signal Recap: Does Lexaria Bioscience Corp offer margin of safetyPortfolio Return Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Aug Outlook: What is Lexaria Bioscience Corp. Equity Warrant s revenue forecastBreakout Watch & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Levels: Can Lexaria Bioscience Corp sustain its profitabilityJuly 2025 Reactions & Accurate Entry/Exit Alerts - baoquankhu1.vn
Jobs Data: Will Lexaria Bioscience Corp Equity Warrant stock go up in YEAR2025 Growth vs Value & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Portfolio Recap: Is Lexaria Bioscience Corp Equity Warrant currently under institutional pressureJuly 2025 Volume & Weekly Return Optimization Plans - baoquankhu1.vn
Aug Sectors: Is Lexaria Bioscience Corp exposed to political riskWeekly Trading Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Market Rankings: Is Lexaria Bioscience Corp benefiting from interest rate changesWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Is Lexaria Bioscience Corp.’s ROE strong enoughJuly 2025 Catalysts & Short-Term High Return Ideas - mfd.ru
Lexaria Bioscience shareholders approve board elections and auditor at annual meeting By Investing.com - Investing.com South Africa
Lexaria Bioscience shareholders approve board elections and auditor at annual meeting - Investing.com Nigeria
Is Lexaria Bioscience Corp. Equity Warrant currently under institutional pressureTake Profit & Safe Capital Growth Tips - mfd.ru
Lexaria Bioscience plummets on $3.5M equity offering - MSN
Is Lexaria Bioscience Corp. exposed to political riskTrade Analysis Report & Accurate Buy Signal Notifications - mfd.ru
Lexaria Awarded Six Additional Patents - New Castle News
Investor Mood: Is Fiverr International Ltd. forming a breakout patternQuarterly Portfolio Report & Weekly High Potential Stock Alerts - baoquankhu1.vn
Lexaria Adds Six Global Patents, Reaches 60 Granted as It Rallies Shareholders Ahead of 2026 Meeting - The Globe and Mail
Lexaria reaches milestone with 60 patents granted worldwide By Investing.com - Investing.com Nigeria
Lexaria Bioscience Expands Global Patent Portfolio to 60 Granted Patents - citybuzz -
LEXX Strengthens Patent Portfolio with New International Approva - GuruFocus
Lexaria reaches milestone with 60 patents granted worldwide - Investing.com
International Business Times - FinancialContent
Aug Big Picture: Can Lexaria Bioscience Corp. ride the EV waveTrade Signal Summary & Fast Gaining Stock Reports - baoquankhu1.vn
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point - Investing News Network
Risk Check: Will Lexaria Bioscience Corp outperform small cap indexesWeekly Stock Report & Reliable Price Action Trade Plans - baoquankhu1.vn
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higherEarnings Summary Report & Fast Moving Market Watchlists - bollywoodhelpline.com
Should I trade or invest in Lexaria Bioscience Corp. Equity WarrantStock Surge & Risk Controlled Swing Trade Alerts - bollywoodhelpline.com
Aug Big Picture: What hedge funds are buying Lexaria Bioscience CorpEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Leaders: Can Lexaria Bioscience Corp ride the EV waveWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-01-15 23:22:36 - baoquankhu1.vn
Levels Update: What are Lexaria Bioscience Corp. Equity Warrant’s earnings expectationsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
Institution Moves: Is Lexaria Bioscience Corp stock a bargain at current levels2025 Valuation Update & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital - TipRanks
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs - Investing.com
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):